BioMarin Outlines Strategy Refresh, Voxzogo Competition, and 40% Margin Goal

Executives detail pipeline, acquisitions, and financial targets at healthcare conference

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

BioMarin Pharmaceutical executives used a conference presentation to outline the company's refreshed strategy, discuss upcoming competitive dynamics for its drug Voxzogo, and frame key growth and margin expectations tied to its rare disease franchises and recent acquisitions. The CEO highlighted business development as a more significant contributor to BioMarin's future, while the CFO projected a 40% operating margin target for 2026 and provided an early outlook on the impact of the pending Amicus acquisition.

Why it matters

As a leading rare disease drugmaker, BioMarin's strategic direction, pipeline progress, and financial performance are closely watched by investors and the broader pharmaceutical industry. The company's ability to navigate competitive threats, execute on acquisitions, and deliver profitable growth will be crucial to maintaining its position in the rare disease space.

The details

BioMarin CEO Alexander Hardy said the company has elevated business development as a more significant contributor to its future, pointing to recent acquisitions of Inozyme and the pending Amicus deal as evidence of that shift. CFO Brian Mueller projected a 40% operating margin target for 2026, excluding the Amicus acquisition, citing a $0.5 billion cost transformation program and 'leveraged growth.' On the Voxzogo drug, Hardy said BioMarin has prepared for competition over the last two years and believes switching will be 'complicated' due to the importance of long-term durability and safety. The company also previewed several upcoming clinical catalysts, including data readouts for its gene therapy programs.

  • BioMarin expects to close the Amicus acquisition in Q2 2026.
  • The ITC matter related to Voxzogo is expected to be heard in April 2026, with a preliminary decision anticipated around August 2026.

The players

Alexander Hardy

Chief Executive Officer of BioMarin Pharmaceutical.

Brian Mueller

Chief Financial Officer of BioMarin Pharmaceutical.

BioMarin Pharmaceutical

A biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases.

Amicus

A biopharmaceutical company that BioMarin is in the process of acquiring.

Voxzogo

BioMarin's drug for the treatment of achondroplasia, the most common form of dwarfism.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.